07:40 AM EDT, 09/30/2024 (MT Newswires) -- Precision BioSciences ( DTIL ) said Monday it submitted clinical trial applications to initiate a phase 1 study to evaluate PBGENE-HBV, its investigative treatment for chronic hepatitis B.
The company said it is expects to begin a phase 1 study soon and to report results next year.